- recruitingPhase I and Phase II (Integrated)- Other
Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors
This study is testing a new cancer medicine called MCLA-129 in adults with advanced lung cancer and other solid tumours. Doctors want to find safe doses and see if giving this drug, on its own or alongside other cancer medicines, helps slow down or shrink tumours.
Belgium · Spain · Netherlands - authorisedHuman Pharmacology (Phase I)- First administration to humans
A PHASE 1 FIRST-IN-HUMAN OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY EFFICACY OF ERAS-0015 MONOTHERAPY AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS
This early-stage clinical trial is testing a new drug called ERAS-0015 in humans for the first time. It is for adults with advanced solid tumours. Doctors want to see how safe the drug is, find the best dose, and check if it can help slow down or shrink tumours.
Spain - authorisedPhase I and Phase II (Integrated)- First administration to humans
A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors
This study is a long-term safety check for adults with advanced solid tumours who have already received an experimental cell therapy called IMA203 or IMA203CD8. Researchers will monitor participants over several years to check for any delayed side effects and see how their immune systems continue to respond.
Germany - recruitingTherapeutic confirmatory (Phase III)
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies
This study tracks the long-term safety and health of adults with solid cancers who previously received a medicine called avelumab (Bavencio) in earlier clinical trials. Researchers want to learn how well the treatment works over several years and check for any late-appearing side effects.
Italy · Bulgaria · Poland - recruitingTherapeutic exploratory (Phase II)
A PHASE II, OPEN LABEL, RANDOMIZED, NON-COMPARATIVE COHORTS STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RISK OF RECURRENCE AND HIGH TUMOR MUTATIONAL BURDEN (TMB-H) OR MICROSATELLITE INSTABILITY (MSI-H) (IMperator)
This study looks at new treatments (atezolizumab and tiragolumab) for people with certain solid cancers that have been removed by surgery. It aims to see if these treatments can help stop the cancer from coming back.
Spain - recruitingPhase I and Phase II (Integrated)- First administration to humans
Study of RP2 alone and in combination with PD1 Blockade in patients with solid tumours
This study is testing a new treatment called RP2, both on its own and with another drug (PD1 Blockade), for people with solid tumours. It's an early-stage study, meaning it's one of the first times this treatment is being given to humans, to see if it's safe and how well it works.
Spain - recruitingPhase I and Phase II (Integrated)- First administration to humans
First-in-human, open-label, multicenter, Phase I/IIa, dose-escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors
This study is testing a new medicine, BNT142, for people with certain advanced solid tumours. It aims to see how safe the medicine is, what side effects it causes, and if it can shrink or stop the growth of the tumours.
Netherlands · Spain · Germany - recruitingHuman Pharmacology (Phase I)- Other
A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours
This study is looking at a medicine called olaparib (also known as Lynparza) in children and young people with solid tumours. We want to see how safe it is, how well it's tolerated, and how the body handles it. This helps us find the right dose for future use.
Italy · Denmark · Hungary - recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
This study is testing a new treatment called RP1, by itself and with another medicine (Opdivo), for adults with various types of cancer (solid tumors). It aims to see how safe the treatment is and if it helps shrink tumors.
Germany · France · Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1 Study of BGB-B3227 Alone and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors
This study is testing a new medicine called BGB-B3227, sometimes combined with another medicine, tislelizumab, for people with advanced solid tumours. It's an early-stage study to see if the treatment is safe and how it works in the body.
Italy - recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients with Injectable Solid Tumors.
This study is testing a new treatment called TILT-123 for people with certain solid cancers that can be injected. Researchers want to find the right dose and see if it's safe. It's an early-stage study, meaning it’s one of the first times this treatment is being tried in humans.
Finland - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Study of EOS006215 in Adult Participants with Advanced Solid Tumors
This early-stage study is testing a new medicine called EOS006215 for adults with advanced solid cancers. It's the first time this medicine is being given to people, to check if it's safe and how it works in the body.
Belgium - recruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
United States · Argentina · Australia - active not recruitingPHASE3
Avelumab Program Rollover Study
This study is for people with solid tumours already receiving a cancer medicine called avelumab in another clinical trial. It aims to safely continue their treatment and closely watch for any side effects, ensuring they receive ongoing care.
United States · Argentina · Australia - active not recruitingPHASE2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
This study is for people with advanced solid cancers that haven't responded to other treatments. It uses a "precision medicine" approach, matching treatments to the specific genetic changes found in each person's tumour, aiming for more effective and personalised care.
United States · Australia · Belgium - active not recruitingPHASE3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.
United States · Australia · Belgium - recruitingPHASE1
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)
This study looks at new treatments, BI 1703880 and Ezabenlimab, for different advanced cancers in adults when other treatments haven't worked. Doctors want to find a safe dose and see if these new drugs help the body fight cancer.
United States · Japan · South Korea - recruitingTherapeutic exploratory (Phase II)
A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed‑Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid Tumors
This study is testing a new combination of two drugs, tiragolumab and atezolizumab, for people with advanced solid tumours. It aims to see how safe the combination is and how the body handles these medicines.
Cyprus · Croatia · Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
Study of GS-4528 for Adults With Solid Tumors
This study is looking into a new medicine, GS-4528, for adults who have solid tumours (like lumps or growths). It's the very first time this medicine is being given to people, so the main goal is to see if it's safe and how the body handles it.
Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination with Atezolizumab in Participants with Advanced and/or Metastatic Solid Tumors
This study is testing a new medicine, RO7284755, by itself or with another drug called Atezolizumab. It's for adults with advanced solid tumours that have spread. The main goals are to see if the treatment is safe and if it can help fight the cancer.
Denmark · Spain · Poland - recruitingHuman Pharmacology (Phase I)- First administration to humans
Phase 1 Study of PYX-106 in Solid Tumors
Researchers are looking into a new medicine called PYX-106 for people with solid tumours (growths in the body). This is a very early study to see if it's safe and how it works in humans for the first time. It's a key first step in developing new treatments.
Spain · Belgium - recruitingHuman Pharmacology (Phase I)- Other
A 3-Part Phase 1 Study to Investigate the Absolute Oral Bioavailability and Absorption, Metabolism, and Excretion of 14C-Unesbulin in Patients With Advanced Solid Tumor
This early-stage study is testing a new medicine called Unesbulin, marked with a special tracer, in people with advanced solid tumours. Researchers want to understand how the body takes in, uses, and gets rid of this medicine when taken by mouth.
Hungary - recruitingPHASE4
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
This study, called FLOTILLA, offers continued access to cancer medicines encorafenib and binimetinib for people who have already taken part in earlier clinical trials. It's for those still benefiting from the treatment.
United States · Australia · Brazil - recruitingPHASE1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
This study is testing a new medicine, INCA33890, for people with advanced or spreading solid cancers. Doctors want to see how safe the medicine is, what side effects it causes, and find the best dose to give.
United States · China · Denmark - active not recruitingPHASE1, PHASE2
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
This study looks at a new drug, ASTX660, for people with advanced cancers like solid tumours and lymphomas. It checks how safe the drug is, the best dose to use, and if it helps shrink tumours, especially when standard treatments aren't working.
United States · Belgium · Canada - active not recruitingPHASE1
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
This study is testing a new drug, GS-9911, by itself or with an antibody treatment, Zimberelimab, for adults with advanced solid cancers. It's the first time in humans, focusing on safety and finding the right dose.
United States · Australia · Canada - active not recruitingPHASE1, PHASE2
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
This study looks at a new treatment called M9140 for different advanced cancers like stomach, lung, and pancreatic cancer. It aims to see if it's safe and effective for patients whose cancers have a specific marker called CEACAM5.
United States · Australia · Austria - active not recruitingPHASE1, PHASE2
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
This study is testing a new cancer medicine, BI-1910, alone and with another drug called pembrolizumab, for people with advanced solid tumours like lung cancer or liver cancer. It aims to find the right dose and check how safe and effective it is.
Denmark · Germany · Spain - active not recruitingPHASE2
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
This study looks at a new drug, palbociclib, combined with standard chemotherapy for children, teenagers, and young adults with certain cancers that have come back or are hard to treat. It aims to find a safe dose and see how well it works.
United States · Brazil · Canada - recruitingPHASE1, PHASE2
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
This study is looking at a medicine called ponatinib for children aged 1 to 17 with certain types of cancer, like leukemia and lymphoma. We want to see how safe it is and how well it works when other treatments haven't helped or aren't suitable.
Belgium · France · Italy - recruitingPHASE2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
This study is testing a new oral medicine, APL-101, for people with advanced cancers. It focuses on lung cancer and other solid tumours where specific genetic changes linked to a protein called MET are found. Researchers want to see how well it works and if it's safe.
United States · Australia · Canada - active not recruitingPHASE1
Phase I Comparative Bioavailability Study
This study looks at how the body uses a new cancer medicine, AZD2281, when given in two different ways. It's for people with advanced solid tumors who have already tried other treatments.
Australia · Belgium · Switzerland - active not recruitingPHASE2
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
This study is looking at a drug called vemurafenib for different advanced cancers. It focuses on cancers with a specific gene change (called BRAF V600 mutation). The study wants to see how well the drug works and if it's safe for patients who have limited other treatment options.
France - active not recruitingPHASE1
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
This study is looking at a new medicine called Runimotamab for people with certain advanced HER2-positive cancers. It aims to see if it's safe and how it works, both alone and with other treatments like Trastuzumab.
United States · Australia · Belgium - active not recruitingPHASE1
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
This study is for adults with advanced cancer that hasn't responded to other treatments. It's testing new medicines, BI 770371 and ezabenlimab, to see how safe they are and what doses patients can comfortably take, hoping to help the immune system fight cancer.
United States · Canada · Japan - recruitingPHASE1
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
This study is testing a new medicine, TYRA-430, for people with advanced liver cancer or other advanced solid tumours that have specific gene changes. Researchers want to see if it's safe and if it can help shrink tumours.
United States · Canada · South Korea - recruitingPHASE3
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
This study is looking at a new medicine called INCB161734, given alongside standard chemotherapy, for advanced pancreatic cancer with a specific genetic change (KRAS G12D). It aims to see if this combination works better and is safe for people who haven't had treatment for their advanced cancer.
United States · Australia · Austria - recruitingPHASE2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This study is for cancer patients who are already taking part in another study using the drug adagrasib. It allows them to continue getting treatment if it's helping. It looks at how well adagrasib works long-term for various solid tumours, alone or with other cancer medicines.
United States · Australia · Belgium - not yet recruitingPHASE2
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This study is for people with advanced solid tumours that have a specific genetic change called an MTAP deletion. It's testing a new medicine, BMS-986504, alone and with other cancer treatments, to see how safe and effective they are.
United States · Belgium · Canada - recruitingPHASE1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
This study is looking at a new treatment called INCB161734 for advanced cancers with a specific genetic change (KRAS G12D mutation). Researchers want to see if it's safe and how well it works, either alone or with other cancer drugs.
United States · Australia · Belgium - active not recruitingPHASE2
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
This study is looking at a new combination treatment, olaparib and pembrolizumab, for adults with advanced cancers. It focuses on specific types of solid tumours that have certain genetic changes or deficiencies in how their cells repair themselves.
United States · Argentina · Australia - active not recruitingPHASE1, PHASE2
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This study is testing a new discovery drug called RO7247669 for advanced cancers. It aims to find the safest and most effective dose, and see if it can shrink certain tumours like melanoma, lung, and oesophageal cancer. The drug works by boosting the body's own immune system to fight cancer.
Denmark · Georgia · Israel - recruitingPHASE1, PHASE2
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
This study is testing a new drug, ORIC-114, for people with advanced cancers that have specific changes in their EGFR or HER2 genes. It's looking at how safe the drug is, the best dose, and if it can shrink tumours, either alone or with chemotherapy.
United States · Australia · Canada - recruitingPHASE1
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
This study is looking at a new medicine called GSK5733584 for people with advanced solid tumours. It aims to see if the treatment is safe, how well the body handles it, and how much of the medicine is in the body over time at different doses.
United States · Argentina · Australia - recruitingPHASE2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
This study is looking into a new medication called plixorafenib for people with certain types of cancer, including brain tumours, that have a specific change in their BRAF gene. It aims to see how well it works and if it's safe.
United States · Australia · Canada - active not recruitingPHASE1
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
This study looks at how your body handles a new cancer drug called cediranib when you also take a common medicine called rifampicin. It helps researchers understand how these drugs work together in patients with advanced solid tumours, aiming for safer and more effective treatments.
Canada · United Kingdom - active not recruitingPHASE1, PHASE2
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This study is for children and teenagers with solid tumours or brain tumours that are advanced or have spread, and for whom standard treatments haven't worked or aren't suitable. It's testing a new medicine called Entrectinib to see if it's safe and effective.
United States · Canada · China - active not recruitingPHASE1
Study of INCB123667 in Subjects With Advanced Solid Tumors
This study is testing a new drug, INCB123667, for people with advanced solid tumours. It will look at how safe the drug is, how it's used with other treatments, and if it could help shrink tumours. It's an early-stage study.
United States · France · Italy - active not recruitingPHASE1
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
This study looks at a new treatment called mRNA-4157, sometimes given with other medicines like pembrolizumab, for different solid cancers. Its main goal is to check how safe it is, how well people tolerate it, and how it affects the body's immune system.
United States · Australia · Japan